Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

WuXi Biologics Prices Hong Kong IPO at $511 Million

publication date: Jun 6, 2017
View a Printer Friendly version of this page, allowing you to print the page.
WuXi Biologics priced its Hong Kong IPO at the top of the range, raising $511 million, according to numerous sources. Demand for the offering was strong, caused by the WuXi pedigree and the fast growing revenues of the biologics business-- up 91% in the first nine months of 2016. The WuXi Biologics offering was 30 times oversubscribed, potential cornerstone investors were turned away, and underwriters closed their books early. The offering values WuXi Biologics at $3 billion, and the new shares are expected to begin trading in Hong Kong on June 13. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China